BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.060
-0.020 (-1.85%)
At close: Apr 10, 2026, 4:00 PM EDT
1.070
+0.010 (0.94%)
After-hours: Apr 10, 2026, 7:28 PM EDT

BioXcel Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-69.9-59.6-179.05-165.76-106.93
Depreciation & Amortization
0.30.310.320.330.3
Stock-Based Compensation
2.776.1618.6117.3419.46
Other Adjustments
10.92-12.863.12.350.31
Change in Receivables
-0.1-0.060.18-0.25-
Changes in Inventories
-0.041.31-0.01-1.99-
Changes in Accounts Payable
6.97-4.33-3.2213.034.85
Changes in Accrued Expenses
--0.742.53.8-
Changes in Other Operating Activities
-8.53-2.222.57-4.2-0.13
Operating Cash Flow
-57.62-72.03-155.01-135.34-82.15
Capital Expenditures
---0.02-0.14-0.45
Investing Cash Flow
---0.02-0.14-0.45
Long-Term Debt Issued
---98.6-
Long-Term Debt Repaid
--2.5---
Net Long-Term Debt Issued (Repaid)
--2.5-98.6-
Issuance of Common Stock
58.1439.6927.540.28102.45
Net Common Stock Issued (Repurchased)
58.1439.6927.540.28102.45
Other Financing Activities
-1.62-0.53-1.02-2.65-
Financing Cash Flow
56.5236.6626.5296.24102.45
Net Cash Flow
-1.1-35.37-128.5-39.2419.85
Free Cash Flow
-57.62-72.03-155.03-135.48-82.6
FCF Margin
-8974.30%-3178.60%-11233.80%-36128.00%-
Free Cash Flow Per Share
-4.72-28.41-85.13-77.38-50.11
Levered Free Cash Flow
-71.2-67.76-176.91-56.32-102.36
Unlevered Free Cash Flow
-51.76-72.91-169.64-148.81-102.37
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q